ClinicalTrials.gg
RecruitingNCT06126315ALCALSUpdated Oct 6, 2026

Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS

A Phase 2/3 interventional study of Acetyl-l-carnitine and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Mario Negri Institute for Pharmacological Research. Recruiting at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Mario Negri Institute for Pharmacological Research · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 6, 202619 sites added19 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy — 27 open to participants now, 36 under way, 7 of them phase 3. Amyotrophic Lateral Sclerosis · Italy.

Planned enrollment
21st of 69
246 · median 87
Started
2025
with 10 others
Phase 2/3
3 of 89
1 open now
Primary completion
2027-04
later than 20 of 35 live
Registered
61st of 89
by date

Among the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, this one is the 21st largest by planned enrollment of the 69 interventional ones that give a count, is one of 11 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 20 of the 35 other live ones, and was the 61st registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

27 of the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the progression of functional disability (loss of self-sufficiency), as measured by the ALSFRS-R scale. Secondary study aims: 1. The effect of ALCAR treatment on different clinical aspects: functional decline as measured by ALSFRS-R total score; the decline of forced vital capacity (FVC); quality of life as measured by ALSAQ-40 scale; cognitive function as measured by Edinburgh Cognitive and Behavioural ALS Screen (ECAS) scale; survival (being alive and without tracheostomy). 2. To measure the effects of ALCAR treatment on disease biomarkers potentially involved in the drug's mechanisms of action. These include PGC-1 alpha, 3-nitrotyrosine (3-NT), acetyl cyclophilin A (acetyl-PPIA), neurofilament light chain (NFL), creatine kinase (CK), Musclin/osteocrin, MyomiRNA (MiR-206), Uric acid, Matrix metalloproteinase-9 (MMP-9), Monocyte Chemoattractant Protein-1 (MCP-1), 4-Hydroxynonenal (HNE). 3. The tolerability and safety of ALCAR treatment by identifying unexpected adverse events.

Study population: 246 subjects will be enrolled on one Australian and ten Italian ALS sites.

Inclusion criteria: subjects aged 18+ years with a diagnosis of ALS according to Gold Coast Criteria; disease duration \<24 months; satisfactory bulbar and spinal function (self-sufficiency evaluated by a score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking); satisfactory respiratory function (FVC ≥80% of predicted); documented progression of symptoms as measured by the ALSFRS-R scale. Disease progression rate (DFS) must be>= 0.33. DFS =(48- ALSFRS-R at screening)/months from onset to screening, treatment with Riluzole in the last four weeks. Exclusion criteria: antecedent polio infection; other motor neuron disease; involvement of other systems possibly determining a functional impairment; other severe clinical conditions; unwillingness or inability to take riluzole; previous use of ALCAR for any reason; inability to understand and comply with the study requirements, and to give written informed consent personally or via their legally authorized representative.

All eligible participants will be randomized to receive ALCAR (1,5 or 3 g/day) or placebo in addition to riluzole 50 mg b.i.d. Permuted block (with a block size of 6), 1:1:1 centralized randomization scheme will be used. The overall treatment duration will be 48 weeks. After enrolment, each participant will be followed up until death. Eligible subjects will be seen after 4, 12, 24, 36 and 48 weeks. At each visit, a general assessment will be made, including vital signs, body mass index (BMI), neurological examination (including quantitative and qualitative evaluation of the motor system), comorbidity, concomitant treatments and adverse events. Blood samples will be collected at baseline -Day 1 (randomization)-, 4, 12, 24, 36 and 48 weeks to test biomarkers. Functional disability will be assessed at each visit using the ALS-FRS-R scale. The respiratory function will be assessed using a spirometer to measure FVC before starting treatment (baseline visit) and at 4, 12, 24, 36 and 48 weeks. Cognitive function will be evaluated at baseline, weeks 24 and 48, using ECAS scale. Health-related quality of life, measured by the ALSAQ-40, will be tested at baseline, 24 and 48 weeks. Compliance will be tested by the local investigators, counting unused packages at each follow-up visit. Pre-planned statistical analyses will be done on Intention-to-treat and Per-protocol (PP) populations. The statistical plan will include descriptive statistics and a comparison of the proportions of self-sufficient participants at week 48 using the chi-square or Fisher's exact test for the primary endpoint. Secondary endpoints measured by numerical scores obtained from clinical scales will be analyzed using repeated measures mixed models, while biomarkers using repeated measures ANOVA. Time-to-event endpoints, such as survival and the probability of remaining self-sufficient over 48 weeks, will be analyzed with Kaplan-Meier curves. The number of adverse events and serious adverse events after 48 weeks will be compared between treatment arms.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18+;
  2. ALS diagnosis according to the Gold Coast Criteria;
  3. Disease duration \< 24 months from symptom onset, as indicated by limb weakness or bulbar symptoms, at the randomization/baseline visit*;
  4. Self-sufficiency [Satisfactory bulbar and spinal function (score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking)];
  5. Satisfactory respiratory function (FVC ≥80% of predicted);
  6. Documented progression of symptoms as measured by the ALSFRS-R scale. Disease progression rate (DFS) must be>= 0.33. DFS =(48- ALSFRS-R at screening)/months from onset to screening.
  7. Ability to understand and comply with the study requirements;
  8. Ability to give written personally or, as an alternative, via a legally authorized representative;
  9. Treatment with riluzole 50 mg twice/day for at least 4 weeks prior to randomization visit;
  10. Intact cognitive function, again determined by the Principal Investigator.

    • The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS.

Exclusion criteria

Exclusion Criteria:

  1. Antecedent polio infection or other active infection;
  2. Motor neuron disease (MND) other than ALS;
  3. Involvement of other systems possibly determining a functional impairment (as measured by the endpoints) for the entire duration of the study;
  4. Other severe clinical conditions (e.g., cardiovascular disorders, neoplasms) with an impact on survival or functional disability in the next 12 months;
  5. Previous use of ALCAR for any reason;
  6. Poor compliance with previous treatments;
  7. Other experimental treatments in the three months prior to the screening visit (if a subject is receiving another experimental drug, a 3-month before participating in the present clinical trial will be required);
  8. Women who are lactating or able to become pregnant (e.g. who are not , surgically sterile, or using inadequate ) and men unable to practice contraception for the duration of the treatment and three months after its completion;
  9. Inability to understand and comply with the study requirements;
  10. Unwillingness or inability to take riluzole.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    alcar 1.5 g

    2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 1.5 g

    Drug: Acetyl-l-carnitine

  • Experimental
    alcar 3 g

    2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 3 g

    Drug: Acetyl-l-carnitine

  • Placebo comparator
    placebo

    2 pockets of placebo will be administered t.i.d for 48 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. self-sufficient

    The proportion of participants remaining self-sufficient after 48 weeks in each treatment arm

    Time frame: 48 weeks

Secondary outcomes

  1. Mean change of ALSFRS-R total score in each treatment arm

    Mean change of ALSFRS-R total score in each treatment arm

    Time frame: from baseline to week 48

  2. Mean change of FVC% in each treatment arm

    Mean change of FVC% in each treatment arm

    Time frame: from baseline to week 48

  3. Mean change in the five domains of ALSAQ-40 measuring different aspects of quality of life (physical mobility, ADL/independence, eating and drinking, emotional reactions, communication) in each treatment arm

    Mean change in the five domains of ALSAQ-40 measuring different aspects of quality of life (physical mobility, ADL/independence, eating and drinking, emotional reactions, communication) in each treatment arm

    Time frame: from baseline to week 48

  4. Mean change in ECAS total score in each treatment arm

    Mean change in ECAS total score in each treatment arm

    Time frame: from baseline to week 48

  5. Cumulative probability of remaining self-sufficient in each treatment arm

    Cumulative probability of remaining self-sufficient in each treatment arm

    Time frame: from baseline to week 48

  6. Cumulative probability of remaining free from a 6-point or greater decline in ALSFRS-R total score in each treatment arm

    Cumulative probability of remaining free from a 6-point or greater decline in ALSFRS-R total score in each treatment arm

    Time frame: from baseline to week 48

  7. Cumulative probability of remaining without gastrostomy in each treatment arm

    Cumulative probability of remaining without gastrostomy in each treatment arm

    Time frame: from baseline to week 48

  8. Cumulative probability of remaining without non-invasive ventilation (NIV) support (≥12 hours a day in a 24-hour period) in each treatment arm

    Cumulative probability of remaining without non-invasive ventilation (NIV) support (≥12 hours a day in a 24-hour period) in each treatment arm

    Time frame: from baseline to week 48

  9. Cumulative survival probability (of being alive and without tracheostomy) in each treatment arm

    Cumulative survival probability (of being alive and without tracheostomy) in each treatment arm

    Time frame: from baseline to week 48

  10. The mean change in the levels of PGC-1 alpha, 3-NT, acetyl-PPIA in the peripheral blood mononuclear cells (PBMCs) and of NFL, MMP-9, MCP-1, CK, MiR-206, Musclin/osteocrin, Uric acid, HNE in plasma in each treatment arm, during the entire treatment period

    The mean change in the levels of PGC-1 alpha, 3-NT, acetyl-PPIA in the peripheral blood mononuclear cells (PBMCs) and of NFL, MMP-9, MCP-1, CK, MiR-206, Musclin/osteocrin, Uric acid, HNE in plasma in each treatment arm, during the entire treatment period

    Time frame: from baseline to week 48

  11. Number of adverse events and serious adverse events in each treatment arm

    Number of adverse events and serious adverse events in each treatment arm

    Time frame: from baseline to week 48

07

Study locations

14 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 25 months after the start.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's planned 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 13, 2023
StartActual
Mar 26, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Sep 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added, 19 sites removed
Show 19 added (18 Italy, 1 Australia)
  • Concord Hospital · Sydney, Australia
  • Fondazione Serena ONLUS Centro Clinico NEMO Brescia · Brescia, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Dipartimento di Neurologia · Bergamo, Italy
  • Istituto Auxologico Italiano, IRCCS Dipartimento di Neurologia · Milan, Italy
  • Azienda Ospedaliera Universitaria Federico II Di Napoli · Naples, Italy
  • Azienda Ospedaliera Universitaria "Luigi Vanvitelli", Dipartimento di Scienze mediche e chirurgiche avanzate · Naples, Italy
  • Azienda Ospedaliero-Universitaria Maggiore della Carità · Novara, Italy
  • Azienda Ospedale-Università di Padova, Unità di Neurologia Clinica · Padova, Italy
  • A.S.P. Palermo, Villa delle Ginestre Hospital · Palermo, Italy
  • Fondazione Serena ONLUS-Centro Clinico NEMO Trento · Pergine Valsugana, Italy
  • Azienda Ospedaliera di Perugia · Perugia, Italy
  • Azienda Ospedaliero Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale · Pisa, Italy
  • San Camillo Forlanini Hospital, Center for Neuromuscolar and Neurological Rare Diseases, Unit of Neurology and Neurophysiopathology · Roma, Italy
  • Fondazione Serena ONLUS - Centro Clinico NeMO Ancona · Torrette, Italy
  • Fondazione Serena ONLUS centro clinico NEMO · Milan, Italy
  • AOU di Modena Nuovo Ospedale Civile S. Agostino Estense di Modena - Ospedale di Baggiovara · Modena, Italy
  • Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS · Pavia, Italy
  • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Università di Roma "La Sapienza" · Roma, Italy
Show 19 removed
  • Concord Hospital · Sydney, Australia
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Dipartimento di Neurologia · Bergamo, Italy
  • Fondazione Serena ONLUS Centro Clinico NEMO Brescia · Brescia, Italy
  • Istituto Auxologico Italiano, IRCCS Dipartimento di Neurologia · Milan, Italy
  • Fondazione Serena ONLUS centro clinico NEMO · Milan, Italy
  • AOU di Modena Nuovo Ospedale Civile S. Agostino Estense di Modena - Ospedale di Baggiovara · Modena, Italy
  • Azienda Ospedaliera Universitaria Federico II Di Napoli · Naples, Italy
  • Azienda Ospedaliera Universitaria "Luigi Vanvitelli", Dipartimento di Scienze mediche e chirurgiche avanzate · Naples, Italy
  • Azienda Ospedaliero-Universitaria Maggiore della Carità · Novara, Italy
  • Azienda Ospedale-Università di Padova, Unità di Neurologia Clinica · Padova, Italy
  • A.S.P. Palermo, Villa delle Ginestre Hospital · Palermo, Italy
  • Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS · Pavia, Italy
  • Fondazione Serena ONLUS-Centro Clinico NEMO Trento · Pergine Valsugana, Italy
  • Azienda Ospedaliera di Perugia · Perugia, Italy
  • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
  • Azienda Ospedaliero Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale · Pisa, Italy
  • San Camillo Forlanini Hospital, Center for Neuromuscolar and Neurological Rare Diseases, Unit of Neurology and Neurophysiopathology · Roma, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Università di Roma "La Sapienza" · Roma, Italy
  • Fondazione Serena ONLUS - Centro Clinico NeMO Ancona · Torrette, Italy
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    19 sites added, 19 sites removed
    Show 19 added (18 Italy, 1 Australia)
    • Concord Hospital · Sydney, Australia
    • Fondazione Serena ONLUS Centro Clinico NEMO Brescia · Brescia, Italy
    • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Dipartimento di Neurologia · Bergamo, Italy
    • Istituto Auxologico Italiano, IRCCS Dipartimento di Neurologia · Milan, Italy
    • Azienda Ospedaliera Universitaria Federico II Di Napoli · Naples, Italy
    • Azienda Ospedaliera Universitaria "Luigi Vanvitelli", Dipartimento di Scienze mediche e chirurgiche avanzate · Naples, Italy
    • Azienda Ospedaliero-Universitaria Maggiore della Carità · Novara, Italy
    • Azienda Ospedale-Università di Padova, Unità di Neurologia Clinica · Padova, Italy
    • A.S.P. Palermo, Villa delle Ginestre Hospital · Palermo, Italy
    • Fondazione Serena ONLUS-Centro Clinico NEMO Trento · Pergine Valsugana, Italy
    • Azienda Ospedaliera di Perugia · Perugia, Italy
    • Azienda Ospedaliero Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale · Pisa, Italy
    • San Camillo Forlanini Hospital, Center for Neuromuscolar and Neurological Rare Diseases, Unit of Neurology and Neurophysiopathology · Roma, Italy
    • Fondazione Serena ONLUS - Centro Clinico NeMO Ancona · Torrette, Italy
    • Fondazione Serena ONLUS centro clinico NEMO · Milan, Italy
    • AOU di Modena Nuovo Ospedale Civile S. Agostino Estense di Modena - Ospedale di Baggiovara · Modena, Italy
    • Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS · Pavia, Italy
    • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
    • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Università di Roma "La Sapienza" · Roma, Italy
    Show 19 removed
    • Concord Hospital · Sydney, Australia
    • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Dipartimento di Neurologia · Bergamo, Italy
    • Fondazione Serena ONLUS Centro Clinico NEMO Brescia · Brescia, Italy
    • Istituto Auxologico Italiano, IRCCS Dipartimento di Neurologia · Milan, Italy
    • Fondazione Serena ONLUS centro clinico NEMO · Milan, Italy
    • AOU di Modena Nuovo Ospedale Civile S. Agostino Estense di Modena - Ospedale di Baggiovara · Modena, Italy
    • Azienda Ospedaliera Universitaria Federico II Di Napoli · Naples, Italy
    • Azienda Ospedaliera Universitaria "Luigi Vanvitelli", Dipartimento di Scienze mediche e chirurgiche avanzate · Naples, Italy
    • Azienda Ospedaliero-Universitaria Maggiore della Carità · Novara, Italy
    • Azienda Ospedale-Università di Padova, Unità di Neurologia Clinica · Padova, Italy
    • A.S.P. Palermo, Villa delle Ginestre Hospital · Palermo, Italy
    • Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS · Pavia, Italy
    • Fondazione Serena ONLUS-Centro Clinico NEMO Trento · Pergine Valsugana, Italy
    • Azienda Ospedaliera di Perugia · Perugia, Italy
    • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
    • Azienda Ospedaliero Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale · Pisa, Italy
    • San Camillo Forlanini Hospital, Center for Neuromuscolar and Neurological Rare Diseases, Unit of Neurology and Neurophysiopathology · Roma, Italy
    • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Università di Roma "La Sapienza" · Roma, Italy
    • Fondazione Serena ONLUS - Centro Clinico NeMO Ancona · Torrette, Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06126315
Collaborators
University of Sydney, FightMND
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Mar 26, 2025
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Elisabetta Pupillo, PharmD
Contact
elisabetta.pupillo@marionegri.it
00390239014605
Elisabetta Pupillo, PharmD
study chair · Istituto Di Ricerche Farmacologiche Mario Negri

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcarnitine

Start the discussion